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The Ten-eleven translocation (TET) enzymes regulate
gene expression by promoting DNA demethylation
and partnering with chromatin modifiers. TET2, a
member of this family, is frequently mutated in hema-
tological disorders. The contributions of TET2 in
hematopoiesis have been attributed to its DNA
demethylase activity, and the significance of its
nonenzymatic functions has remained undefined.
To dissect the catalytic and non-catalytic require-
ments of Tet2, we engineered catalytically inactive
Tet2 mutant mice and conducted comparative ana-
lyses of Tet2 mutant and Tet2 knockout animals.
Tet2 knockout mice exhibited expansion of hemato-
poietic stem and progenitor cells (HSPCs) and devel-
oped myeloid and lymphoid disorders, while Tet2
mutant mice predominantly developed myeloid ma-
lignancies reminiscent of human myelodysplastic
syndromes. HSPCs from Tet2 knockout mice ex-
hibited distinct gene expression profiles, including
downregulation of Gata2. Overexpression of Gata2
in Tet2 knockout bone marrow cells ameliorated dis-
ease phenotypes. Our results reveal the non-cata-
lytic roles of TET2 in HSPC homeostasis.INTRODUCTION
The Ten-eleven translocation (TET) family of dioxygenases (Tet1/
2/3) are DNA-modifying enzymes expressed in various embry-
onic and adult cell types, including hematopoietic stem cells
(HSCs) (Cimmino et al., 2011; Tahiliani et al., 2009). They regulate
gene expression in part by promoting active and passive DNA2480 Cell Reports 28, 2480–2490, September 3, 2019 ª 2019 The Au
This is an open access article under the CC BY-NC-ND license (http://demethylation through the conversion of 5-methylcytosine
(5mC) to 5-hydroxymethylcytosine (5hmC) and other oxidized
derivatives (Ito et al., 2010, 2011; Tahiliani et al., 2009). TET2 is
a unique member of this family that is highly expressed in the he-
matopoietic lineages. It is one of the most frequently mutated
genes in myelodysplastic syndrome (MDS), an incurable clonal
hematological disorder marked by pronounced reductions in
blood cell production, significant dysplasia in the cells produced,
or some combination of both (Tefferi and Vardiman, 2009). Loss-
of-functionmutations in the TET2 gene are seen in20%ofMDS
cases and almost 50% of chronic myelomonocytic leukemia
(CMML) patients (Abdel-Wahab et al., 2009; Delhommeau
et al., 2009; Kosmider et al., 2009; Song et al., 2013). While
most mutations lead to loss of the entire protein, some are only
missensemutations involving either the catalytic or non-catalytic
domains (Abdel-Wahab et al., 2009; Sato et al., 2016). Deletion of
Tet2 in mice increases HSC self-renewal and restricts differenti-
ation, causing CMML-like disease with aggressive metastases
(Li et al., 2011; Moran-Crusio et al., 2011). In addition, loss of
TET2 has been linked to lymphoid disorders, as a fraction of
Tet2 knockout (KO) mice developed aberrant lymphopoiesis,
and somatic mutations of TET2 have been found in subtypes
of lymphoid malignancies (e.g., angioimmunoblastic T lym-
phomas, 33%; diffuse large B cell lymphomas, 10%; and
mantle cell lymphoma, 4%) (Asmar et al., 2013; Dominguez
et al., 2018; Lemonnier et al., 2012; Mouly et al., 2018; Pan
et al., 2017; Quivoron et al., 2011; Reddy et al., 2017).
The catalytic activity of Tet2 is mainly confined to its C termi-
nus, which alone can promote DNA hydroxylation (Tahiliani
et al., 2009). Tet2 has also been implicated in formation of chro-
matin regulatory complexes with O-linked N-acetylglucosamine
transferase (OGT) and histone deacetylases (HDACs) to regulate
transcription and histone modifications (Chen et al., 2013; Wil-
liams et al., 2011; Wu et al., 2011; Zhang et al., 2015). Thus far,
the contributions of Tet2 to hematopoiesis have largely been
studied using conventional or conditional KO mouse modelsthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Generation of Tet2 Catalytic Mutant (Mut) Mouse and Characterization of Its Hematological Phenotypes
(A) Tet2 wild-type (WT) and catalytic Mut proteins (top) and alleles (bottom).
(B and C) Analysis of the genotypes of Tet2 catalytic Mut mice by RFLP (restriction fragment length polymorphism) (B) and Sanger sequencing (C).
(legend continued on next page)
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that lack the entire Tet2 protein. Such an approach, despite inter-
rogating the full functions of Tet2, fails to define or distinguish be-
tween its catalytic and non-catalytic requirements in a physio-
logically relevant context. In this study, to comprehensively
dissect endogenous and physiologically relevant Tet2 functions
during normal and abnormal hematopoiesis in vivo, we gener-
ated Tet2 catalytically inactive mice by mutating the enzymatic
pocket of the protein and conducted a comparative analysis of
the resulting Tet2 mutant (Mut) mice with Tet2 KO mice. While
both groups developed symptoms of hematological disorders
early in life and had similar survival rates, differences in the dis-
ease spectrum were found between the cohorts; Tet2 KO mice
developed both myeloid and lymphoid disorders with increased
hematopoietic stem and progenitor cell (HSPC) fractions. In
contrast, in Tet2 Mut mice, aberrant hematopoiesis was
restricted largely to the myeloid lineage. Our study establishes
that the role of Tet2 in hematopoietic system goes beyond its
catalytic functions and identifies distinct non-catalytic require-
ments for Tet2 in the HSPC homeostasis, as well as in the onset
of aberrant lymphopoiesis.
RESULTS
Generation of Tet2 Catalytic Mut Mice
To establish the distinct contributions of catalytic functions of
Tet2 to hematopoietic homeostasis, we developed a mouse
strain lacking only the catalytic activity of Tet2. We generated a
Tet2 catalytic-deficient allele (Tet2m) by introducing amino acid
substitutions H1367Y and D1369A in the catalytic domain of
Tet2 protein using CRISPR/Cas9-based gene editing in embry-
onic stem cells (ESCs) (Figure 1A). A properly targeted heterozy-
gous Tet2m/+ ESC clone was injected into blastocysts to
generate chimeric mice (Figure S1A), which were bred to wild-
type (WT) C57/BL6 mice to first generate Tet2m/+ and then, after
intercrossing, Tet2m/m mice (here after referred to as Tet2 Mut)
(Figures 1B and 1C). The Tet2 Mut mice, like a previously used
strain of Tet2/mice (Tet2 KO) (Li et al., 2011), were born in ex-
pected Mendelian ratios and grew normally in a 129Sv-C57/BL6
mixed background (Figures S1B–S1D). The expression of Tet2
was comparable in Tet2 Mut and WT HSPCs (LinSca-1+c-Kit+(D) Tet2 mRNA levels in LinSca-1+c-Kit+ (LSK) cells of indicated genotypes qua
mRNA in knockout (KO) but its normal expression in Mut samples.
(E) Tet2 protein levels in total bone marrow isolated from 4-month-old mice asses
intensity is shown. Note the absence of Tet2 protein in KO but its normal and co
(F) Levels of 5hmC in the bone marrow of the indicated genotypes, assessed by do
control samples) (n = 3).
(G) Overview of experimental platform using Tet2 WT, Mut, and KO mice.
(H) Blood counts of Tet2 Mut and KO mice (4 months old, n = 8).
(I) Representative smears of peripheral blood (PB) of 10-month-old Tet2Mut (ii), Te
mice (i). Images of representative dysplastic hematopoietic cells found in Tet2Mut
and KO mice show dysplastic erythroid cells (polychromatophilic, blue arrowhead
outlined arrowhead; immature erythroid cells, blue-outlined arrowhead). Dysplas
immature B cells (black arrows [h and i]) are shown. All images are taken at 310
(J) Representative flow data for myeloid and lymphoid lineages in PB from Tet2M
(10 months old). Flow data for WT control are also shown (left).
(K) Percentages ± SEM of CD11b+ (left), c-Kit+ (middle), and B220lowCD19+CD43
mice (10 months old).
Error bars indicate SD unless otherwise specified. n.c. stands for no significant c
2482 Cell Reports 28, 2480–2490, September 3, 2019cells) at the mRNA level (Figure 1D) and in total bone marrow
at the protein level (Figure 1E). 5hmC levels in DNA isolated
from 2-month-old Tet2 Mut bone marrow cells was reduced by
60% and was similar to the level present in age-matched
Tet2 KO cells (Figure 1F). The Tet2 KO mice lack all functions
of the enzyme, while the Tet2 Mut mice only lack the enzymatic
activity of the protein. Therefore, Tet2 Mut mice, in conjunction
with Tet2 KO and WT mice, comprise a viable platform for
comparative physiological, cellular, and molecular analyses to
dissect the catalytic-dependent and independent functions of
Tet2 in HSPCs and MDS etiology (Figure 1G).
Analysis of Peripheral Blood of Tet2 Mut Mice
At 4 months of age, Tet2 Mut mice exhibited normal blood
counts of the peripheral blood (PB) (Figure 1H). A trend of slightly
higher white blood cell (WBC) counts was found in Tet2KOmice,
but they had a normal range of red blood cell (RBC) and platelet
counts (Figure 1H). Likewise, amild increase in CD11b+ cells was
observed in Tet2 KOmice, but flow cytometric analysis of PB re-
vealed no significant dyspoiesis in either Tet2 KO or Tet2 Mut
mice (Figure S1E).
At 10 months of age, Tet2 Mut mice showed no significant
blood count abnormalities (except for mild reductions in Hgb
andHct). In contrast, Tet2KOmice exhibited higherWBCcounts
with moderate anemia and lower platelet counts (data not
shown). PB smear specimens revealed that Tet2 Mut mice had
multilineage dysplastic features, much like those found in human
MDS (Giagounidis and Haase, 2013; Goasguen and Bennett,
1992; Komrokji et al., 2010;Wang, 2011). Dysplasia inmonocytic
lineages was predominant, but defective erythroid maturation
and dysplastic platelets and neutrophils were also noted (Figures
1I and S1F). Flow cytometry analysis confirmed these myelopro-
liferative phenotypes in PB of Tet2Mut mice (Figures 1J, 1K, and
S1G). As previously reported (Ko et al., 2011; Li et al., 2011;
Moran-Crusio et al., 2011; Quivoron et al., 2011), one-third of
Tet2 KO mice developed human MDS-like phenotypes (Figures
1J and 1K; KO [myeloid]). However, in a few Tet2 KO mice
(<5%), a moderately increased frequency of CD3e+ cells alone
was the predominant phenotype (Figure S1H; KO [T cell]). Impor-
tantly, a significant portion (more than one-fourth) of Tet2 KOntified by qRT-PCR. Data are normalized to Gapdh. Note the absence of Tet2
sed by western blot. Quantified Tet2 signal intensity normalized to actin signal
mparable expression in Mut and WT samples.
t blot and quantified as average of three separated experiments (relative toWT
t2 KOwith MDS-like myeloid (iii), and lymphoid (iv) phenotypes andWT control
and KOmice are also shown (right; b–j, higher magnification images). Tet2Mut
; Howell-Jolly bodies, black arrowhead; other poikilocytes [e.g., echinocytes],
tic myeloid cells (d and f) and dysplastic platelets (giant platelet, g), as well as
0 magnification. Scale bars, 10 mm.
ut mice (middle) and Tet2 KO mice with myeloid and B cell phenotypes (right)
+ (in Gr-1CD4/8 cells, right) cells in the PB in Tet2Mut (n = 6) and KO (n = 8)
hange. See also Figure S1.
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Figure 2. Analysis of Tet2 Mut and KO Mouse Bone Marrow
(A) Percentages of the indicated fractions in the bone marrow of Tet2 Mut and KO mice (4 months old) (n = 6).
(B) Bone marrow flow analysis for myeloid and lymphoid cells from Tet2 Mut and KO mice (10 months old).
(legend continued on next page)
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mice in study succumbed to aberrant lymphopoiesis, and these
B cell phenotypes weremore prevalent than dysplasia inmyeloid
or erythroid lineages (Figures 1J and 1K). Morphological analysis
found immature forms of B lymphocytes in the PB of these mice.
These were of small to medium size (cell diameter is 1.5–2 times
that of an erythrocyte) and displayed scanty, round, and baso-
philic cytoplasm and clumped nuclear chromatin with relatively
round nuclear outline, which are comparable morphological fea-
tures to human chronic lymphocytic leukemia (CLL) or small lym-
phocytic lymphoma (SLL) (Figure 1I, KO [B cell] and Figure S1F,
KO [lymphoid]). Flow cytometry assays showed an increase in
B220mid cells, which are CD19+CD43+, implying defective differ-
entiation in the B cell lineage (Figures 1J and 1K).
Characterization of Hematopoietic Phenotypes in Tet2
Mut and Tet2 KO Bone Marrow
At 4 months of age, Tet2 Mut mice displayed a skewed
myeloid/lymphoid ratio in the bone marrow (Figures 2A,
S2A, and S2B). Similarly, Tet2 KO mice with aberrant lymphopoi-
esis predominantly showed maturation defects in the B cell
lineage, and these phenotypes became more striking with
age (Figures 2B–2D, S2C, and S2D). Flow cytometric analysis of
the bone marrow confirmed myeloproliferative phenotypes in
10-month-old Tet2 Mut mice (Figures 2B and S2D). Notably,
Tet2 KO mice with myeloid disorders displayed similar myeloid
proliferative phenotypes with analogous onset and severity (Fig-
ure S2D). In contrast, a portion of Tet2 KO mice succumbed to
B-lymphoid disorders, and a clear expansion of Gr-1CD4/
8B220midCD19+CD43+IgM+ abnormal B cells was observed in
the bone marrow. These B cells reside in CD5+, phenotypic B-1a
lymphocytes, which have been suggested to relate to human
CLL (Figure2B;Yuetal., 2015). ThesedefectiveB-1ahomeostasis
are consistentwith theCLL-likemorphological abnormalities inPB
from Tet2 KOmice (Figures 1K, 2B, and S2D).
The skewed myeloid/lymphoid ratio observed in bone
marrow of Tet2Mutmice was also found at the progenitor stage;
the myeloid-progenitor-enriched fractions (LinSca-1c-Kit+
cells) increased, while the lymphoid progenitors (common
lymphoid progenitor [CLP]) were mildly decreased (Figures 2C,
2D, and S2C). MEP (megakaryocyte-erythroid progenitor)
levels decreased and GMP (granulocyte-macrophage progeni-
tor) levels increased in Tet2 Mut mice (Figures 2C and 2D).
Tet2 KO mice with lymphoid phenotypes also displayed
increased frequency of myeloid-progenitor-enriched fractions,
but these increases were mainly attributed to higher numbers
and frequency of MEPs. Common myeloid progenitor (CMP)
levels decreased, while CLP levels were relatively maintained
(Figures 2C and 2D). HSPCs were then analyzed. At 10 months,(C and D) Representative flow data for myeloid progenitors and HSPCs in the b
indicated fractions (percentage in LinSca1–c-Kit+ cells for CMPs, GMPs, and ME
and percentage in CD135LSK cells for CD150+ HSCs) (n = 6).
(E) Tet2-KO HSPCs have increased replating capacity compared to Tet2-Mut HS
(F) Representative images of May-Gr€unwald-Giemsa-stained cytospin preparat
second replating). Metamyelocytes, myelocytes, and matured granulocytes cons
Tet2 Mut and KO colonies (also see Figure S2H). Scale bars, 10 mm.
HSPCs,hematopoietic stemandprogenitor cells; LSK,Linc-Kit+Sca-1+;MEP,meg
GMP, granulocyte-monocyte progenitor, LinSca-1c-Kit+CD16/32highCD34+; C
common lymphoid progenitor, LinIL7Ra+c-KitmidSca-1+. Error bars indicate SD. n
2484 Cell Reports 28, 2480–2490, September 3, 2019a higher number and frequency of LSK (LinSca-1+c-Kit+)
cells and CD135LSK cells were found in Tet2 KO mice,
but not in Tet2 Mut mice (Figures 2C, 2D, and S2D; data not
shown). Furthermore, the frequency of HSC-enriched fractions
(CD150+CD48CD135LSK cells) increased in Tet2 KO mice,
regardless of having a myeloid or lymphoid phenotype (Figures
2C, 2D, and S2D).
These findings prompted us to subject HSPCs from 4-month-
old WT, Tet2 Mut, and KO mice to in vitro serial replating assay.
We observed in the first plating that the Tet2-KO HSPCs
produced fewer colonies compared to Tet2Mut or control cells,
and a slightly increased ratio of macrophage colonies was found
in Tet2Mut colonies (Figure S2E). However, after a third round of
replating, Tet2-KO HSPCs exhibited increased colony-forming
capacity compared to Tet2 Mut and WT controls, and this
phenotype was still pronounced in the next rounds of replating
(Figure S2F). By 10 months of age, these phenotypes were
evenmore evident; when Tet2Mut or KO colonies were replated,
both Tet2Mut and KO cells produced more colonies in the sec-
ond plating, and maintained this ability through serial replatings
(Figures 2E and S2G). Notably, a comparison of third and fourth
round of replating revealed that Tet2-KO HSPCs can produce a
higher number of colonies than Tet2-Mut HSPCs (Figure 2E).
Microscopic analysis of colonies formed after the second replat-
ing confirmed an increase in immature and dysplastic myeloid
cells in Tet2 Mut and KO colonies (Figures 2F and S2H). These
analyses established that the non-catalytic functions of Tet2
have distinct contributions to HSPC biology.
Distinct Disease Spectrum of Tet2 Mut and KO Mice
Both Tet2 Mut and KO mice exhibited splenomegaly and
swollen lymph nodes, with an 10-fold increase in spleen
weight over age-matched controls (Figures 3A and 3B; not
shown). The increased spleen sizes in Tet2 Mut mice and in
Tet2 KO mice with myeloid phenotypes were attributed to
myeloid infiltration (Figures 3C, 3D, and S3; data not shown).
In Tet2 KO mice with lymphoid phenotypes, immature B cells
had increased in the spleen. Spleens were infiltrated with small
to medium-sized, regular nuclear-contoured lymphoid cells in a
diffuse pattern (Figures 3C, 3D, and S3). These phenotypes
were even more evident at 10 months of age (Figures S3B
and S3C).
Next, we compared the onset of hematological disorders
and other signs of poor health in Tet2 Mut with Tet2 KO mice.
The Tet2 KO and Tet2 Mut cohorts displayed similar overall
survival, with 50% of animals dying by 450 days and majority
by 800 days, while WT mice survived beyond 2 years (Fig-
ure 3E). Likewise, the two groups had similar incidence ofone marrow from Tet2 Mut and KO mice (10 months old). Percentages of the
Ps; percentage in LinCD127+ cells for CLPs; percentage in Lin cells for LSK;
PCs (10 months old, up to fourth -round replating data) (n = 3).
ions of the colonies formed by HSPCs from Tet2 WT, Mut, and KO mice (at
ist of WT colonies, and immature and dysplastic myeloid cells are increased in
akaryocyte-erythrocyteprogenitor, LinSca-1c-Kit+CD16/32low/negCD34low/neg;
MP, common myeloid progenitor, LinSca-1c-Kit+CD16/32lowCD34+; CLP,
.c. stands for no significant change. See also Figure S2.
AB
C
E
D
F
G
H I
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splenomegaly, and age-matched moribund Tet2 Mut and KO
mice had no significant differences in spleen size or weight (Fig-
ures 3A and 3F). However, most strikingly, despite the similar
survival and disease onset of Tet2 Mut and KO mice, the dis-
ease spectrum of Tet2 Mut was different from that of Tet2 KO
mice: while Tet2 KO mice developed both myeloid and
lymphoid malignancies (44.4% and 38.9% [8/18 and 7/18],
respectively), 78.5% (11/14) of Tet2Mut mice in our cohort dis-
played blood phenotypes restricted to the myeloid lineage by
10 months (Figure 3G).
These malignancies were readily transplantable. All recipient
mice transplanted with Tet2 Mut donor marrow cells initiated
the lethal forms of myeloid disorders within 6 weeks (Figure 3H),
and the resulting hematological phenotypes were similar to
those observed in primary Tet2 Mut mice. Monocyte-enriched
CD11b+ cells were increased, accompanied by dysplasia and
c-Kit+myeloid blasts (Figure 3I; data not shown). Likewise, recip-
ient mice transplanted with donor marrows from Tet2 KO mice
with B cell phenotypes developed lethal lymphoid disorders
within 6 weeks, similar to the ones observed in primary Tet2
KO mice (Figures 3H and 3I).
Distinct Gene Expression Changes in Tet2 Mut versus
KO HSPCs
To gain molecular insights into the catalytic and non-catalytic
functions of Tet2 in HSPCs, we analyzed the gene expression
profiles of 2-month-old Tet2 Mut, Tet2 KO and WT HSPCs
(LSK) and Lin cells by RNA sequencing (RNA-seq) (Figure 4A–
4F and S4A). We found 167 differentially expressed genes
(DEGs) in Tet2-KO LSK (60 up, 107 down) compared to 568
DEGs in Tet2-Mut LSK cells (244 up, 344 down) (Figure 4A). Like-
wise, there were 197 DEGs in Tet2-KO Lin cells (106 up, 91
down) versus 180 DEGs in Tet2-Mut Lin cells (97 up, 83
down) (Figure 4D). Notably, in both LSK and Lin– cells, most
DEGs were changed by less than two fold, suggesting that in
young progenitor cells gene expression changes due to either
Tet2 deficiency or loss of its catalytic activity are mostly subtle.
However, comparison of the DEGs by clustering analysis (Fig-
ures 4B and 4E, left panels) or Venn diagrams (Figures 4B and
4E, right panels, and Figure S4B) revealed that the LSK and
Lin cells from Tet2 Mut and KO mice exhibited distinct gene
expression profiles. Consistently, Gene Ontology enrichment
analysis of DEGs in Tet2 Mut and KO samples identified both
common and distinct Gene Ontology (GO) terms, including cell
proliferation, differentiation, gene regulation, and apoptosis (Fig-Figure 3. Characterization of Hematological Malignancies in Tet2 Cata
(A and B) Spleen weight (n = 3–6; A, left). Representative images of spleens fro
phenotypes (A, right) (10 months old). Representative images of lymph nodes fro
(C and D) Representative flow data for myeloid and lymphoid lineages in spleens f
lymphoid phenotypes (C, bottom) (10 months old). The percentages of indicated
(E and F) Kaplan-Meier survival curves of overall survival (E) and splenomegaly-fr
shown in parenthesis. Log-rank test was used to generate p values.
(G) Disease spectrum in Tet2 Mut and KO mice (n = 16, 18, respectively).
(H and I) Schematic of transplantation of diseased bone marrow (H, top). Surviva
recipient mice transplanted with Tet2 Mut bone marrow developed lethal mye
(H, bottom). Representative flow cytometric analysis for myeloid and lymphoid line
bone marrow, 3 weeks after BMT are shown.
Error bars indicate SD. n.c. stands for no significant change. See also Figure S3
2486 Cell Reports 28, 2480–2490, September 3, 2019ures 4C and 4F). This analysis suggests that complete loss of
Tet2 or loss of its catalytic activity alone leads to subtle but
distinct changes in the gene expression programs of HSPCs.
Next, we integrated the RNA-seq data with the available Tet2
chromatin immunoprecipitation sequencing (ChIP-seq) datasets
from WT mouse bone marrow (Deplus et al., 2013) and
compared Tet2-bound genes with the list of DEGs. Approxi-
mately 50% of DEGs in Tet2-Mut and Tet2-KO LSK cells, as
well as 30% of DEGs in Tet2-Mut and Tet2-KO Lin cells,
were bound by Tet2 (i.e., direct targets of Tet2) (Figures 4G
and S4C). Classification of Tet2 peak location at these direct
target genes revealed that over 80% of Tet2 binding occurred
at promoters (Figure 4H). These genes with Tet2 binding at pro-
moters included several regulators of HSCs and lineage speci-
fiers. Among them, two transcription factors, Hoxa9 and
Gata2, were significantly downregulated in Tet2-KO, but not in
Tet2-Mut, LSK, or Lin cells, respectively (Figure 4I). Other reg-
ulators of HSCs such asGata1 and Spi1were not affected, while
Tet1 was downregulated in both Tet2-Mut and Tet2-KO LSK
cells, and Tet3 expression was marginally reduced in Tet2-KO
LSK cells (Figure S4D). Next, we examined whether the reex-
pression of selected identified downstream effectors of non-cat-
alytic roles of Tet2, such as Gata2, can rescue disease pheno-
types observed in Tet2 KO mice. Gata2 overexpression in Tet2
KO bone marrow cells ameliorated lymphoid disease pheno-
types and conferred significant survival advantage (Figures 4J,
4K, S4E, and S4F). However, in Tet2 Mut bone marrow cells, it
failed to rescue myeloid phenotypes (Figure 4K). Collectively,
our findings suggest that the Tet2 catalytic activity primarily reg-
ulates the myeloid lineage, while its non-catalytic functions
modulate the lymphoid lineage. As such, loss of Tet2 enzymatic
activity alone predominantly leads to myeloid malignancies,
while complete loss of Tet2 influences the hemostasis of both
myeloid and lymphoid lineages, leading to aggressive malig-
nancies of cell types of both lineages (Figure 4L).
DISCUSSION
Tet2 loss causes progressive defects in hematopoiesis, such as
increased HSC self-renewal, and has been implicated in both
myeloid and lymphoid disorders (Asmar et al., 2013; Dominguez
et al., 2018; Lemonnier et al., 2012; Mouly et al., 2018; Pan et al.,
2017; Quivoron et al., 2011; Reddy et al., 2017). The analysis of
our cohorts of Tet2Mut and KOmice have provided three lines of
evidence that together establish the biological requirementslytic Mut Mice
m Tet2 Mut mice with myeloid phenotypes and Tet2 KO mice with lymphoid
m Tet2 Mut mice with myeloid phenotypes (B).
rom Tet2Mut mice with myeloid phenotypes (C, middle) and Tet2 KOmice with
fractions in spleens from Tet2 Mut and Tet2 KO mice are shown (D, n = 6).
ee survival (F) of Tet2Mut and KO mice. The number of mice in each group are
l curve of transplanted mice (H, bottom, n = 10 for Mut, 9 for WT and KO). All
loid malignancies within 6 weeks after bone marrow transplantation (BMT)
ages in PB of recipient mice transplanted with Tet2Mut (I. top) or KO (I. bottom)
.
A D
B E
C F
G H J K
I L
Figure 4. Gene Expression Profiling of Tet2 Mut and KO HSPCs
(A) MA plot of RNA-seq analysis of 2-month-old LSK cells as log2 fold change versus mean gene expression levels. Differentially expressed genes (DEGs) are
depicted in red. Mut or KO groups are compared to WT.
(legend continued on next page)
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of the non-catalytic functions of Tet2 to HSPC maintenance and
tumor suppression: (1) loss of Tet2, compared to loss of its cat-
alytic activity alone, leads to greater expansion of HSPCs and
enhanced colony formation; (2) Tet2 Mut mice predominantly
develop myeloid malignancies, while Tet2 KO mice develop
both myeloid and lymphoid disorders; and (3) despite similar
5hmC levels, Tet2-KO and Tet2-Mut HSPCs have different
gene expression profiles, and Tet2-KO HSPCs express reduced
levels of HSC lineage specifiers Gata2 and Hoxa9. These find-
ings provide conceptual advances to our understanding of
requirements of Tet2 in hematopoiesis. The current dogma
primarily attributes the contributions of Tet2 in HSPCs and he-
matological disorders to its enzymatic or DNA demethylase ac-
tivity (Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al.,
2011; Tahiliani et al., 2009). Our work shifts this ‘‘paradigm’’ by
associating the catalytic and non-catalytic roles of Tet2 to
distinct disease etiologies involving the myeloid and lymphoid
lineages, respectively.
Increased incidence of aberrant lymphopoiesis is a distinct
feature of Tet2 loss that is not seen in Tet2 Mut mice,
suggesting that Tet2 non-catalytic roles are involved in regulation
of lymphopoiesis. Interestingly, 30% of Tet2 KO mice
showed the accumulation of phenotypic B-1a lymphocytes,
B220lowCD19+IgM+CD43+CD11blowCD5+ cells, and developed
B cell neoplasms that are comparable to human CLL. We
note that mantle cell lymphoma is also a CD5+ B cell neoplasm,
and the abnormal B cells found in Tet2KOmice are CD23mid pos-
itive (Figure S3B). However, these cells showed no Ccnd1 upre-
gulation (data not shown), and the pathological and morpholog-
ical features observed in Tet2-loss-induced neoplasms classify
them as a CLL-like disorder. Intriguingly, TET2 mutations are
rare (2.3%) in human CLL, but there are also several reports
of loss of TET2 function in B cell lymphomagenesis with blockade
of plasma cell differentiation (Asmar et al., 2013; Dominguez et al.,
2018; Lemonnier et al., 2012; Mouly et al., 2018; Pan et al., 2017;
Quivoron et al., 2011; Reddy et al., 2017).
Establishing the mechanisms by which Tet2 deficiency leads
to diverse hematological abnormalities is critical for understand-
ing how Tet2 regulates normal hematopoiesis and how its down-
regulation or mutations as seen in various cancers contribute to(B) Heatmap of differentially expressed genes identified by RNA-seq across LSK c
comparisons are displayed. Intensity values are log2 transformed (left) and color
overlap between all DEGs in Tet2-Mut and Tet2-KO LSK cells (right).
(C) Selected terms from GO and KEGG analysis of DEGs in LSK cells. Data are pl
(D) MA plot of RNA-seq analysis of 2-month-old Lin cells as log2 fold change ver
(E) Heatmap (left) of DEGs identified by RNA-seq across Lin cells of indicated ge
displayed. Venn diagram illustrating the overlap between all DEGs in Tet2-Mut a
(F) Selected terms from GO and KEGG analysis of DEGs in Lin cells. Data are pl
(G) Comparison of DEGs with Tet2 ChIP-seq peaks in bone marrow, revealing tha
cells are bound by Tet2 (i.e., direct targets of Tet2). Tet2 ChIP-seq data were fro
(H) Classification of Tet2 peaks at DEGs revealing that Tet2 binding is enriched a
(I) Relative expression levels of Hoxa9 and Gata2mRNA in LSK or Lin cells from
qRT-PCR (n = 3). Data normalized to Gapdh.
(J and K) Overexpression of Gata2 in the bone marrow of Tet2 Mut or KO mi
competitive BMT (mixture of test cells [Ly45.2] with competitor [Ly45.1/45.2] in a 1
3 weeks after BMT is shown in (J) (n = 4), and the survival curve of transplanted
(L) Model summarizing the effects of loss of Tet2 versus loss of its catalytic acti
malignancies.
Error bars indicate SD. n.c. stands for no significant change. See also Figure S4
2488 Cell Reports 28, 2480–2490, September 3, 2019tumorigenesis. This is of paramount significance in therapeutic
strategies for hematological disorders involving loss of TET2.
Analysis of our Tet2 Mut mouse model conclusively establishes
that the catalytic activity of Tet2 is the prime regulator of myeloid
lineage and MDS pathogenesis. This suggests that Tet2 targets
affected in MDS are regulated by the enzymatic activity of Tet2
through DNA demethylation. Consistently, DNA hypermethyla-
tion is a hallmark of hematologic disorders, and DNA demethy-
lating agents such as 5-Aza-20-deoxycytidine (decitabine) are
used to treat higher-risk MDS and acute myeloid leukemia (Fa-
biani et al., 2010; Garcia-Manero and Fenaux, 2011; Gardin
and Dombret, 2017; Issa et al., 2004). Likewise, vitamin C (which
boosts TET enzymatic activity) has been shown to be of thera-
peutic benefit in MDS and CMML disease in mice haploinsuffi-
cient for Tet2 (Agathocleous et al., 2017; Cimmino et al., 2017).
Since our model attributes regulation of lymphopoiesis and sup-
pression of lymphomagenesis to the non-catalytic roles of Tet2,
it is likely that such treatments might not be as effective in TET2-
loss-driven lymphoid disorders. Here, we identify key transcrip-
tion factors and lineage specifiersHoxa9 andGata2 as direct tar-
gets of Tet2 that are deregulated in Tet2 KO, but not Tet2 Mut,
HSPCs. We have shown that Gata2 can rescue lymphoid-asso-
ciated phenotypes observed in Tet2 KO mice. Further work will
determine how these genes are regulated in a Tet2 catalytic-in-
dependentmanner, possibly involvingOGT and or HDAC2 (Chen
et al., 2013; Zhang et al., 2015). Identification of additional cata-
lytic and non-catalytic targets and mechanisms of Tet2 that are
distinctly associated with myeloid versus lymphoid diseases
will further enhance our understanding of how TET2 contributes
to HSPC maintenance and suppresses hematological disorders
and malignancies. This will substantially impact strategies for
how TET2 should be targeted for therapeutic purposes.STAR+METHODS
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Antibodies
Anti-Tet2 Abcam Cat# ab124297; RRID: AB_2722695
Anti-Actin Abcam Cat# AC-15; RRID: AB_1658432
Anti-5hmC Active Motif Cat# 39770; RRID: AB_10013602
Goat Anti-Rabbit IgG-HRP CalBiochem Cat# 401393-2ML; RRID: AB_437797
Goat Anti-Mouse IgG-HRP CalBiochem Cat# 401253; RRID: AB_437779
CD4 (GK1.5) BD Bioscience Cat# 553728; RRID: AB_395012
B220 (RA3-6B2) BD Bioscience Cat# 553086; RRID: AB_394616
TER-119 (TER-119) BD Bioscience Cat# 553672; RRID: AB_394985
CD11b (M1/70) BD Bioscience Cat# 553309; RRID: AB_394773
CD19 (1D3) BD Bioscience Cat# 553784; RRID: AB_395048
CD43 (S7) BD Bioscience Cat# 560663; RRID: AB_1727479
NK-1.1 (PK136) BD Bioscience Cat# 553163; RRID: AB_394675
c-Kit (2B8) BioLegend Cat# 105826; RRID: AB_1626278
Gr-1 (RB6-8C5) BioLegend Cat# 108404; RRID: AB_313369
CD135 (A2F10) eBiosciences Cat# 12-1351-82; RRID: AB_465859
CD34 (RAM34) eBiosciences Cat# 11-0341-85; RRID: AB_465022
Sca-1 (D7) eBiosciences Cat# 25-5981-81; RRID: AB_469668
CD3e (145-2C11) eBiosciences Cat# 13-0031-85; RRID: AB_466320
CD8 (53-6.72) eBiosciences Cat# 13-0081-85; RRID: AB_466347
IgM (II/41) eBiosciences Cat# 13-5790-85; RRID: AB_466676
CD71 (R17217) eBiosciences Cat# 11-0711-82; RRID: AB_465124
CD127 (A7R34) eBiosciences Cat# 12-1271-82; RRID: AB_465844
CD45.2 or Ly5.2 (104) eBiosciences Cat# 11-0454-82; RRID: AB_465061
CD45.1 or Ly5.1 (A20) eBiosciences Cat# 25-0453-81; RRID: AB_469628
Streptavidin-APC-eFluor780 eBiosciences Cat# 47-4317-82; RRID: AB_10366688
Streptavidin-PerCP-Cy5.5 eBiosciences Cat# 45-4317-82; RRID: AB_10311495
Critical Commercial Assays
RNAeasy Mini kit QIAGEN 74104
Superscript III first strand Invitrogen 18080-400
XtremeGene 9 DNA transfection reagent Roche 06365787001
Deposited Data
RNA-seq data This paper GEO: GSE132090
Experimental Models: Organisms/Strains
Tet2 –/– (Tet2 KO) mouse Li et al., 2011 N.A.
Tet2 m/m (Tet2 Mut) mouse This paper N.A.
B6.SJL-Ptprca Pepcb/BoyJ Jackson lab 002014
Oligonucleotides
RT-qPCR primers, see Table S1 This paper n/a
Genotyping Primers, see Table S1 This paper n/a
gRNA oligos for gene targeting, see Table S1 This paper n/a
Recombinant DNA
Topo pcr2.1 donor vector This paper n/a
pX330-Tet2-gRNA This paper n/a
FUW-ires-puro This paper n/a
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Software and Algorithms
Trim galore v0.4.1 Github https://github.com/FelixKrueger/TrimGalore
Tophat v2.0.13 John Hopkins University https://ccb.jhu.edu/software/tophat/index.shtml
HTSeq v0.6.1 Anders et al., 2015 https://github.com/simon-anders/htseq
Cufflinks v2.2 Trapnell et al., 2010 http://cole-trapnell-lab.github.io/cufflinks/
DESeq2 v1.20.0 Love et al., 2014 http://www.bioconductor.org/packages/release/bioc/
html/DESeq2.html
DAVID 6.8 Jiao et al., 2012 https://david.ncifcrf.gov/
GraphPad Prism 7 GraphPad https://www.graphpad.com/
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/LEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new unique reagents. Further information and requests for resources and reagents (including mouse
strains, cell lines and plasmids generated in this study) should be directed to and will be fulfilled by the Lead Contact, Ke.I.
(keisuke.ito@einstein.yu.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
A gene block carrying nucleotide substitutions in Tet2 exon 9 to introduce point mutations H1367Y and D1369A into the enzymatic
pocket of Tet2 was synthesized (Table S1) and cloned into Topo PCR2.1 vector. This donor plasmid along with a pX330 plasmid ex-
pressing Cas9 and a gRNA against Tet2 exon 9 (Table S1) were used for gene editing in V6.5 mESCs (background: mixed 129/B6,
sex: male) following our previously published protocols (Wang et al., 2013). Thesemutations only changed the conserved HRD amino
acids in the iron-binding site of the catalytic domain to YRA. They are shown to render the enzyme catalytically inactive without
compromising the stability or localization of Tet2, and in vitro biochemical and in vivo overexpression systems have confirmed their
lack of activity on methylated DNA (Ito et al., 2010; Tahiliani et al., 2009). Targeted clones were screened by RFLP (restriction frag-
ment length polymorphism) using a unique HaeIII restriction site introduced with silent mutations in the Tet2 mutant allele. Properly
edited clones were verified by Sanger sequencing. A heterozygote Tet2+/m ESC clone was injected into mouse blastocysts at the
Einstein Transgenic Core facility. Chimeric animals were bred to wild-type mice to obtain Tet2m/m (Mut) mice. Tet2–/– (KO) mice, pub-
lished previously (Li et al., 2011), were obtained from Dr. Mingjing Xu (University of Maimi). Tet2 KO and Tet2 Mut mice were inter-
crossed to avoid any variations due to background differences between the different groups. Cohorts of Tet2+/+ (wild-type), Tet2 KO
and Tet2 Mut mice (consisting of equal number of male and female animals in each group) were established and housed in an SPF
(Specific-pathogen-free) barrier facility. All animals in this study included both sexes and were in a mixed 129/B6 background. An-
imals were examined weekly for distended belly, enlarged lymph nodes and spleen, overall mobility, and health. The peripheral blood
of moribund animals was collected for analysis. Moribund animals were scarified and hematopoietic tissues including spleen, lymph
nodes and bone marrow were subjected to further histological and flow cytometric evaluation to characterize the disease. All studies
were performed in accordance with our IACUC approved protocols overseen by the Institute for Animal Studies at Albert Einstein
College of Medicine.
METHOD DETAILS
5hmC quantification
DNA was isolated from total bone marrow of 3-month-old mice and analyzed by dot blot using anti 5hmC antibody (Active Motif)
following manufacturer protocol. Breifly, DNA was spotted in replicates on Hybond N+ membranes, dried at room temperature,
blocked in 5% milk and then probed with anti 5hmC antibody (Active Motif 1:10,000) for 1hr followed by three 10min washes in
PBST. Membrane was probed with secondary HRP-conjugated anti rabbit antibody (1:500) for 1hr and washed three times with
PBST before developing using ECL western blot detection reagent and autoradiogrpahy. 5hmC signal intensity was quantified by
ImageJ software (Schneider et al., 2012) and plotted as the average of three independent experiments.
Western blot
Bone marrow from 4-month-old mice was isolated, lysed with laemmmli sample buffer, and boiled. Lysates were resolved on
6%–10% SDS-PAGE (Mini-PROTEAN electrophoresis chamber, Bio-Rad), and transferred on PVDF membranes (Mini Trans-Blote2 Cell Reports 28, 2480–2490.e1–e4, September 3, 2019
apparatus, Bio-Rad) following manufacturer’s protocols. Membranes were blocked in 5% milk in PBS with 0.1% tween (PBST) and
incubated overnight at 4C, or for 1hr at room temperature with primary antibodies (Tet2 ab124297, abcam 1:1000, and Actin AC-15,
abcam 1:40000). Secondary antibody incubations (HRP-anti mouse, 401253, or anti rabbit, 401393, 1:5000, CalBiochem) were car-
ried out for 1hr at room temperature. Protien signal was detected using ECL western blot detection reagent and autoradiogrpahy.
Protein signal intensity was quantified by ImageJ. Tet2 signal was normalized to actin signal.
Flow cytometry
For flow cytometric analyses, we used monoclonal antibodies specific for the following: CD135 (A2F10), CD34 (RAM34), Sca-1 (D7),
CD3e (145-2C11), CD8 (53-6.72), IgM (II/41), F4/80 (BM8), CD71 (R17217), CD127 (A7R34), CD23 (B3B4), CD24 (M1/69), CD45.2 or
Ly5.2 (104), and CD45.1 or Ly5.1 (A20); all were from eBioscience. CD4 (GK1.5), B220 (RA3-6B2), TER-119 (TER-119), CD11b
(M1/70), CD19 (1D3), CD43 (S7) and NK-1.1 (PK136) were from BD Bioscience. CD150 (TC15-12F12.2), CD48 (HM48-1), c-Kit
(2B8) and Gr-1 (RB6-8C5) were from BioLegend. A mixture of monoclonal antibodies against CD4, CD8, CD3e, B220, TER-119,
CD11b, Gr-1, IgM, CD19, CD127, andNK-1.1 was used as a lineagemarker (Lineage). WhenCLLwas assessed, the antibody against
CD127 was not included in the lineage mixture. In some experiments, Streptavidin-APC-eFluor 780 (47-4317) or -PerCP-Cy5.5
(45-4317) was used as a secondary antibody.
Colony formation assay
The colony formation assaywas performed usingMethoCult GFM3434 (StemCell Technologies, Vancouver, BC, Canada) according
to the manufacturer’s instructions. Briefly, the flow sorted Lin–Sca-1+c-Kit+ cells (500 cells/plate, triplicate culture) were seeded into
methylcellulose-based medium, and colonies were counted under microscope after 7 days incubation at 37Co, 5% CO2. GEMM,
Colony-forming unit-granulocyte, erythroid, macrophage, and megakaryocyte; GM, Colony-forming unit-granulocyte and macro-
phage;M, Colony-forming unit-macrophage; E, Burst-forming unit-erythroid. Long-term cultures and in vitro replating assaywas per-
formed as previously reported (500 Lin–Sca-1+c-Kit+ cells/replicate, triplicate culture) (Ito et al., 2012; Ito et al., 2016; Song et al.,
2013). Frequencies of cells with colony forming capacity after long-term in vitro culture were calculated using a limiting-dilution
method (maximum likelihood from the proportion of negative wells measured for each input dilution of cells tested) (Purton and Scad-
den, 2007). In each experiment, at least 12 replicates of each dilution were performed, and a split-plot analysis of variance was used
to investigate the difference between the two conditions.
Analysis of hematopoiesis
The collected peripheral blood was smeared for May-Gr€unwald-Giemsa staining, and/or subjected to an automated blood count. In
some cases, hematological organs, including bone marrows and spleens, were sampled and subjected to evaluate the infiltration of
the hematological disorders. To determine the in vivo transplantability of the disease, 1.0 3 105 bone marrow mononuclear cells
(BMMNCs) from primary deceased Tet2 Mut, Tet KO mice or littermate controls (Ly5.2) were transplanted into irradiated recipient
mice (Ly5.1) with 4.0 3 105 competitor BMMNCs (Ly5.1/2). Donor (Ly5.2) cells were reconstituted. Repopulation of donor myeloid
and lymphoid cells were monitored, and in some experiments, donor contribution to the immature hematopoietic lineages also
evaluated.
Gene expression profiling by RNA-seq analysis
LSK and Lin– cells were sorted from pooled bone marrow of two 10-week-old mice and RNA was extracted using QIAGEN RNAeasy
Kit. RNA was amplified and barcoded and used to prepare libraries of two technical replicates, with ERCC spike in controls. The li-
braries were subjected to 150bp paired-end sequencing (Illumina HiSeq 2500 platform) at the Einstein Epigenomics core. This gener-
ated 1540 million read pairs per sample. The reads were trimmed using the TrimGalore (v 0.4.1, https://github.com/FelixKrueger/
TrimGalore) to remove adaptors and then mapped to the mouse genome (mm10) by TopHat2 software (v 2.0.13) with default param-
eters (Kim et al., 2013). The read pair numbers mapped to individual genes in the Refseq gene annotation (downloaded from the
UCSC genome browser in 03/2017) were calculated with the software HTseq (v 0.6.1) (Anders et al., 2015) using ‘‘–s reverse’’ param-
eter. The Fragments Per Kilobase of transcript per Million (FPKMs) were calculated using the Cufflinks package (v 2.2.1) (Trapnell
et al., 2010). Read counts at the genes with FPKM > 1 were determined by the DESeq2 software (Love et al., 2014) for differential
expression. False Discovery Rate (FDR) < 0.05 was used for selecting differentially expressed genes (DEGs) between Tet2 Mut
and wild-type or Tet2 KO and wild-type samples. Gene Ontology (GO) analysis was performed by DAVID (Jiao et al., 2012)
(https://david.ncifcrf.gov/tools.jsp). Bubble plots were used to show enriched GO terms and KEGG pathways. In the bubble plots,
enrichment factors were calculated as the ratio of gene counts that mapped to a certain pathway versus the total gene number of
that pathway. The expression patterns of the combined DEGS were identified by hierarchical clustering and displayed as heatmap.
Tet2 ChIP-seq peaks were obtained from a previous study of bone morrow (Deplus et al., 2013). They were first converted to the
mm10 version using the LiftOver tool from the UCSC genome browser, and then associated to genes and separated into promoter
peaks (< +/ 2kb of transcription start sites; TSSs), gene body peaks, or distal regulatory peaks (< +/50 kb of start and end of
genes). Genes associated with Tet2 peaks were considered as Tet2 bound genes and compared to the list of DEGs. The RNA-
seq gene expression datasets have been deposited in the Gene Expression Omnibus database.Cell Reports 28, 2480–2490.e1–e4, September 3, 2019 e3
RT-qPCR
RNA from LSK or Lin– cells sorted from two-month-old mouse bonemarrowwas isolated using Qaigen RNAeasy Kit and subjected to
cDNA synthesis using Superscript III First-Strand synthesis system, Invitrogen. Real time quantitative PCR was performed using
SYBR green master mix (Applied Biosystems) in QunatStudio 6 Flex Real-Time PCR system following standard protocols. Relative
gene expression level was analyzed by comparative Ct method and was normalized to Gapdh. Primer sequences for all genes are
shown in supplemental information (Table S1).
Gata2 lentiviral preparation and transduction of bone marrow
HA-taggedmouseGata2was cloned into FUW-ires-Puro vector. Lentivirus was prepared by transfecting FUW-HA-mGata2 or empty
vector into HEK293T cells along with viral packing plasmids (pPAX2 and pMDG) using X-tremeGENE DNA transfection reagent
(Roche) following manufacturer’s protocol. Media was refreshed after 16hrs. Viral soup was harvested 24hr and 48hr later. Bone
marrow isolated frommoribundmicewas cultured, transduced for 24hrs and then selected for 24hrs in puromycin (1ug/mL). Selected
cells were subjected to hematopoietic analyses by FACS and transplantation studies as explained above.
QUANTIFICATION AND STATISTICAL ANALYSES
Data were processed and analyzed in Graphpad PRISM software. Log rank, one-way ANOVA and Student t test were utilized to
determine statistical significance unless otherwise specified. P-values lower than 0.05 were considered statistically significant. Sta-
tistical methods for analysis of genomewide datasets involving RNA-seq are explained in detail under the respective sections as part
of the detailed methods.
DATA AND CODE AVAILABILITY
The RNA-seq datasets have been deposited in the Gene Expression Omnibus (GEO) database (Accession number GSE132090).
Mouse strains, cell lines and plasmids generated in this study will be made available upon request.e4 Cell Reports 28, 2480–2490.e1–e4, September 3, 2019
